- Raw materials
- Bronchodilators
- Fenoterol
Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Fenoterol API Manufacturers & Suppliers
4 verified results
Commercial-scale Suppliers
Employees: 350+
All certificates
All certificates
All certificates
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Fenoterol | CAS No: 13392-18-2 | GMP-certified suppliers
A medication that provides bronchodilation for asthma management by relaxing airway smooth muscles, facilitating improved airflow and relief of bronchoconstriction in respiratory conditions.
Therapeutic categories
Primary indications
- Fenoterol is used for the treatment of asthma
Product Snapshot
- Fenoterol is available as inhalation aerosols, solutions, sprays, powders, and oral syrups, primarily formulated as respiratory and oral small molecules
- It is indicated for the treatment of asthma
- Fenoterol is approved for use in the Canadian market and is also in investigational status
Clinical Overview
Pharmacodynamically, fenoterol exerts its effects by stimulating beta-2 adrenergic receptors located on bronchial smooth muscle cells. This receptor activation leads to relaxation of the smooth muscle, resulting in bronchodilation and an increase in airway airflow. The drug thereby facilitates relief of bronchoconstriction that characterizes obstructive airway diseases such as asthma.
Fenoterol’s mechanism of action involves selective binding to beta-2 receptors, minimizing activity at beta-1 receptors in cardiac tissue; however, systemic administration may still influence heart rate and blood pressure. The compound’s onset of action is rapid, supporting its use in acute bronchospasm, but dosing and formulation must be carefully managed to reduce potential side effects.
Available data on the absorption, distribution, metabolism, and excretion (ADME) profile of fenoterol indicate it is effective via inhalational routes for local lung effects. Metabolism primarily occurs hepatically, with excretion through renal pathways. The drug’s pharmacokinetic profile supports its targeted delivery and rapid onset with manageable systemic exposure.
Safety considerations with fenoterol include its potential to induce tachycardia, hypertension, and other sympathetic nervous system effects, consistent with its classification as an adrenergic agent. Overdose risks and adverse effects necessitate careful clinical monitoring, particularly in patients with cardiovascular comorbidities. Its use as a tocolytic is less common and generally restricted to specific clinical circumstances.
Fenoterol is marketed under various regional brands and is typically formulated as inhalants for asthma therapy. Due to its classification and pharmacological profile, API sourcing requires rigorous quality control to ensure purity, stability, and compliance with pharmacopeial standards. Suppliers must provide thorough certification to support regulatory submissions and guarantee batch-to-batch consistency.
Identification & chemistry
| Generic name | Fenoterol |
|---|---|
| Molecule type | Small molecule |
| CAS | 13392-18-2 |
| UNII | 22M9P70OQ9 |
| DrugBank ID | DB01288 |
Pharmacology
| Summary | Fenoterol is a beta adrenergic receptor agonist primarily targeting beta-2 receptors in bronchial smooth muscle. Its mechanism induces relaxation of airway smooth muscle, leading to bronchodilation and improved airflow. The drug is indicated for managing bronchoconstriction in asthma. |
|---|---|
| Mechanism of action | Beta(2)-receptor stimulation in the lung causes relaxation of bronchial smooth muscle, bronchodilation, and increased bronchial airflow. |
| Pharmacodynamics | Fenoterol is a beta agonist designed to open up the airways to the lungs by decreasing bronchconstriction. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Beta-2 adrenergic receptor | Humans | agonist |
| Beta-1 adrenergic receptor | Humans | agonist |
| Beta-3 adrenergic receptor | Humans | agonist |
ADME / PK
| Metabolism | Hepatic. |
|---|
Formulation & handling
- Fenoterol is a small molecule primarily formulated for respiratory administration via inhalation, with additional oral and buccal forms available.
- Its moderate water solubility and LogP indicate suitability for aerosol and solution formulations targeting pulmonary delivery.
- Absorption of fenoterol is unaffected by food intake, simplifying dosing with regard to meals.
Regulatory status
| Lifecycle | The API's primary patents have expired or are nearing expiry in Canada, allowing for generic entries and increased market competition. As a result, the product is entering a mature market phase with established therapeutic use. |
|---|
| Markets | Canada |
|---|
Supply Chain
| Supply chain summary | Fenoterol is produced by a limited number of originator companies with branded products primarily marketed in Canada. The presence of multiple dosage forms, including inhalation solutions and tablets, indicates an established manufacturing footprint. Patent expiries suggest the potential for existing or upcoming generic competition in the market. |
|---|
Safety
| Toxicity | Symptoms of overdose include angina (chest pain), dizziness, dry mouth, fatigue, flu-like symptoms, headache, heart irregularities, high or low blood pressure, high blood sugar, insomnia, muscle cramps, nausea, nervousness, rapid heartbeat, seizures, and tremor. |
|---|
- Fenoterol may cause cardiovascular adverse effects including angina, arrhythmias, and blood pressure fluctuations in cases of overdose
- Central nervous system symptoms such as dizziness, headache, seizures, and tremors have been observed with excessive exposure
- Monitor for metabolic disturbances such as hyperglycemia and muscle cramps during handling or formulation
Fenoterol is a type of Bronchodilators
Bronchodilators are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) primarily used in the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). These medications function by relaxing and widening the airways in the lungs, thus facilitating easier breathing.
Bronchodilators can be classified into two main types: beta-agonists and anticholinergics. Beta-agonists, including drugs like salbutamol and formoterol, work by stimulating beta receptors in the smooth muscles of the airways, leading to their relaxation and dilation. This action allows more air to pass through the bronchial tubes and improves airflow to the lungs.
Anticholinergics, such as ipratropium bromide and tiotropium, function by blocking the action of acetylcholine, a neurotransmitter that contracts the smooth muscles in the airways. By inhibiting the effects of acetylcholine, anticholinergics promote bronchial muscle relaxation, leading to expanded airways and increased airflow.
These bronchodilator APIs are typically formulated into inhalers, nebulizers, or oral medications to deliver the active ingredients directly to the lungs. The precise dosage and administration route may vary based on the severity of the respiratory condition and the patient's individual needs.
Bronchodilators play a crucial role in managing respiratory disorders and improving patients' quality of life. They are commonly prescribed by healthcare professionals and are often used in combination with other medications, such as corticosteroids, to achieve optimal therapeutic outcomes. It is important to note that the use of bronchodilators should be carefully monitored and controlled under the guidance of a healthcare professional to ensure proper efficacy and minimize potential side effects.
Fenoterol API manufacturers & distributors
Compare qualified Fenoterol API suppliers worldwide. We currently have 4 companies offering Fenoterol API, with manufacturing taking place in 3 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Boehringer Ingelheim | Producer | Germany | Unknown | CEP, CoA, FDA, GMP | 35 products |
| Lusochimica | Producer | Italy | Italy | CoA, JDMF | 23 products |
| Miat | Producer | Italy | Italy | CoA | 10 products |
| Vamsi Labs | Producer | India | India | CEP, CoA, FDA, GMP, ISO9001, USDMF, WC, WHO-GMP | 29 products |
When sending a request, specify which Fenoterol API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Fenoterol API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
